



Ind-Swift Laboratories Limited

Registered Office

SCO 850, Shivalik Enclave,
NAC Manimajra, Sector 13,
Chandigarh – 160101 INDIA

✉ info@indswiftlabs.com

☎ 0172-2730503, 2730920, 5061851-53

CIN No. L24232CH1995PLC015553

Ref: ISLL:CH:2026

Date: 24th February, 2026

To
Department of Corporate Services,
BSE Limited
Phiroze Jeejeebhoy Towers,
25th Floor, Dalal Street,
Mumbai 400 001

To
Department of Corporate Services,
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor
Plot No. C/2, G-Block,
Bandra Kurla Complex, Bandra (E),
Mumbai 400 051

BSE Scrip Code: 532305

NSE Symbol: INDSWFTLAB

Subject: Outcome of the meeting of the Preferential Issue Committee of the Board of Directors of Ind-Swift Laboratories Limited (“the Company”) in accordance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/Ma’am,

With reference to the captioned subject and in accordance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform your good office that the Preferential Issue Committee of the Board of Directors of Ind-Swift Laboratories Limited (“the Company”) at their meeting held on Tuesday, February 24, 2026, has, inter alia, considered and approved the allotment of 51,00,000 Equity Shares of face value of ₹ 10/- each pursuant to the conversion of 51,00,000 Fully Convertible Warrants (“Warrants”), allotted on August 30, 2024, at an issue price of ₹ 121/- each to Essix Biosciences Limited, belonging to Promoter & Promoter Group on preferential basis.

Consequent to the said allotment, the Paid-up Equity Share Capital of the Company stands increased to ₹86,71,15,580/- (Rupees Eighty-Six Crores Seventy-One Lakhs Fifteen Thousand Five Hundred and Eighty Only) divided into 8,67,11,558 (Eight Crore Sixty-Seven Lakh Eleven Thousand Five Hundred and Fifty-Eight) Equity Shares of face value of ₹10/- each.

Details as required under Regulation 30 of the SEBI Listing Regulations read with SEBI Master Circular HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 dated January 30, 2026, with respect to the Preferential Allotment is enclosed as Annexure A.

The meeting of the Preferential Issue Committee of the Board of Directors was commenced at 05:00 P.M. and concluded at 05:30 P.M.

This is for your information and records.

Thanking you,
Yours faithfully,
For Ind-Swift Laboratories Limited



Pardeep Verma
VP-Corporate Affairs & Company Secretary

Manufacturing Facilities:

Unit I: NH-21, Village Jawaharpur, Tehsil Derabassi, District SAS Nagar (Mohali), Punjab – 140507

Unit II: Phase 1, SIDCO Industrial Growth Centre, Samba, Jammu & Kashmir - 184121

☎ 0172-2730503, 2730920, 5061851-53 ✉ info@indswiftlabs.com 🌐 www.indswiftgroup.com

Follow us:

For verifying authenticity of this letter, please reach us by sending copy of same on hr.ho@indswiftlabs.com



Ind-Swift Laboratories Limited

Registered Office

SCO 850, Shivalik Enclave,
NAC Manimajra, Sector 13,
Chandigarh – 160101 INDIA

✉ info@indswiftlabs.com

☎ 0172-2730503, 2730920, 5061851-53

CIN No. L24232CH1995PLC015553

Annexure A

Details on Preferential Allotment in terms of SEBI Master Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026:

S. No.	Particulars	Disclosures
1.	Type of securities proposed to be issued	Equity shares with face value of ₹10/- each pursuant to the conversion of warrants.
2.	Type of issuance	Preferential allotment under Chapter V of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 and other applicable law.
3.	Total number of securities proposed to be issued or total amount for which the securities will be issued	Allotment of 51,00,000 equity shares of face value ₹10/- each, pursuant to conversion of 51,00,000 Fully Convertible Warrants (“Warrants”), against the receipt of the balance subscription amount aggregating to ₹ 46,28,25,000/-
4.	Name and number of the Investor(s)	Name: Essix Biosciences Limited Number: 1 (One)
5.	Post allotment of securities- outcome of the subscription	Pursuant to the aforesaid allotment, the issued, subscribed and paid-up share capital of the Company stands increased in the manner as set out in the letter above.
6.	Issue price / allotted price (in case of convertibles)	Rs. 121/- (Rupees One Hundred Twenty-One Only) per Equity Share.
7.	In case of convertibles - intimation on conversion of securities or on lapse of the tenure of the instrument	The allottee mentioned above have exercised their rights and converted their 51,00,000 Warrants into Equity Shares.

Manufacturing Facilities:

Unit I: NH-21, Village Jawaharpur, Tehsil Derabassi, District SAS Nagar (Mohali), Punjab – 140507

Unit II: Phase 1, SIDCO Industrial Growth Centre, Samba, Jammu & Kashmir - 184121

☎ 0172-2730503, 2730920, 5061851-53 ✉ info@indswiftlabs.com 🌐 www.indswiftgroup.com

Follow us:

For verifying authenticity of this letter, please reach us by sending copy of same on hr.ho@indswiftlabs.com